Diabetology and Endocrinology
Outline
Our department has a new structure as of January 2022. We are committed to promoting basic and clinical research to help diabetic patients lead a life equivalent to non-diabetic people. It is crucial to prevent complications. We will advocate for early therapeutic intervention to prevent cardiovascular complications and microvascular complications such as nephropathy. Moreover, we must aim to preserve and improve patients' quality of life through their diabetes care and treatment. As for research methods, continuing basic research using conventional mice and cells is essential, and we will actively conduct ethically-sound human studies to build evidence useful in daily clinical practice. In this process, we will apply various advanced clinical examination techniques and make full use of data analysis using digital devices and artificial intelligence in line with the current era. As a clinical department of a private medical university, we will continue to promote challenging and rewarding research for all department members.
e-mail: endocrin@kanazawa-med.ac.jp
Faculty
Professor and Chair
Associate Professor
Assistant Professor
Assistant Professor
Adjunct Lecturer
KONISHI Kazunori
Adjunct Lecturer
SHIGIYAMA Fumika
Adjunct Lecturer
贬滨搁鲍惭础 厂丑颈驳别苍辞谤颈
91猎奇 Achievements
Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study.
Takeda Y, Furuhashi M, Sakuma I, Hiramitsu S, Okada M, Ueda S, Kumashiro N, Sakurai M.
Front Endocrinol. 2025 May 1:16:1549687. 2025.
Empagliflozin reduces liver fibrosis by restoring catechol-O-methyltransferase activity associated with magnesium levels.
Hayashi Y, Kawakita E, Kumashiro N, Iijima H, Koya D, Kanasaki K.
Sci Rep. 15(1):27310 doi: 10.1038/s41598-025-12813-x. 2025.
Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: a sub-analysis of the DIVERSITY-CVR study.
Takuma K, Fuchigami A, Shigiyama F, Kumashiro N, Hirose T.
Diabetes Obes Metab. 25: 2131-2141. 2023.
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with nonalcoholic fatty liver disease: a prospective randomized study.
Hiruma S, Shigiyama F, Kumashiro N.
Diabetes Obes Metab. 25: 1576-1588. 2023
External 91猎奇 Funding
Manpei Suzuki Diabetes Foundation, Naoki Kumashiro, 2025-2027
Grant-in-Aid for Scientific 91猎奇 (C), Naoki Kumashiro, 2024-2026